Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase

Dolutegravir (DTG) is the latest antiretroviral (ARV) approved for the treatment of human immunodeficiency virus (HIV) infection. The G118R substitution, previously identified with MK-2048 and raltegravir, may represent the initial substitution in a dolutegravir resistance pathway. We have found tha...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Virol
Autores principales: Quashie, Peter K., Oliviera, Maureen, Veres, Tamar, Osman, Nathan, Han, Ying-Shan, Hassounah, Said, Lie, Yolanda, Huang, Wei, Mesplède, Thibault, Wainberg, Mark A.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2014
Materias:
Vaccines and Antiviral Agents
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4337543/
https://ncbi.nlm.nih.gov/pubmed/25552724
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.03353-14
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares